S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Anne S. Tsao(The University of Texas MD Anderson Cancer Center), Karen Kelly(Cancer Research Center), Tawee Tanvetyanon(Moffitt Cancer Center), David R. Gandara(University of California, Davis), Mary W. Redman(Fred Hutch Cancer Center), T. Barbara(Cornell University), Ying‐Qi Zhao(Fred Hutch Cancer Center), Janet Tu(The University of Texas MD Anderson Cancer Center), Martin J. Edelman(Fox Chase Cancer Center), Jonathan W. Riess(University of California Davis Medical Center), Jhanelle E. Gray(Moffitt Cancer Center), Ming-Hui Hsieh(Cancer Research And Biostatistics), Marianna Koczywas(City Of Hope National Medical Center)
JTO Clinical and Research Reports
October 17, 2024
10.1016/j.jtocrr.2024.100738
Cited by 4

Related Papers

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k